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1. Introduction 
Gliomas are the commonest brain tumours. They are tumours derived from the three most 
common glial cells, the astrocytes, oligodendrocytes and ependymal cells, with each cell 
type giving rise to its named tumour i.e. astrocytoma, oligodendroglioma and 
ependymoma. Other less abundant glial cells give rise to rarer tumours e.g. subependymal 
astrocytes leading to subependymoma. Table 1 summarises the different gliomas, their 
incidences and subtypes (Bigner et al, 1996; Han et al, 2010, Kozak & Moody, 2009; Louis et 
al, 2007). The grading depends on the number of histological features of malignancy such as 
cellular atypia, presence of mitoses, endothelial proliferation, and necrosis and is known as 
the World Health Organisation grade (WHO). For the astrocytomas, grade I has none, grade 
II has one feature, grade III (anaplastic astrocytoma) has two and grade IV (glioblastoma) 
has three or four. The majority of gliomas arise in the brain, with only a minority in the 
spinal cord.  
Surgery for brain tumours is very different from surgery for peripheral tumours. The major 
difference is that brain tumours directly affect mental function. The effect on quality of life is 
therefore more pronounced than a peripheral tumour causing a physical disability in 
isolation. Unlike other major cancers such as breast, lung and colon where large advances 
have been made over the last twenty years (Office for National Statistics, 2010), little 
advance has been made with brain tumours. As a result, the mortality of patients with 
glioblastoma (grade IV astrocytoma) has not improved much over this period (Cancer 
Research UK, 2010; Erridge et al, 2011). 
In this chapter we will consider surgery for gliomas. Surgery has a role to play in virtually 
all gliomas at some stage or another. The extent of surgery varies from a simple biopsy, to 
establish diagnosis, to a more radical attempt at complete removal. Although some surgical 
principles universally apply, in many cases management varies from country and country, 
and even from centre to centre e.g. treatment of an elderly person with glioblastoma may 
vary from palliative care with no treatment, to maximal debulking followed by radiotherapy 
and chemotherapy. Some of these decisions on how aggressive one should treat the patient 
depend not only on surgical accessibility of the lesion but also on family views, cultural 
values and of course cost and availability of resources for neurosurgery. Such life-death 
decisions are part of the daily routine of neurosurgical practice.  
Prolonging life may be less important than maximising quality of life. Sometimes the two go 
hand in hand, however in other circumstances, the extra time gained by surgery may result 
in a life of misery spent in hospital feeling sick on drugs with questionable benefit.  
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Glial cell Sub-category WHO Grade Variants Epidemiology 
Astrocyte Pilocytic 1  M : F, 1.2:1 
0.3/100,000 
 Diffusely infiltrating 2 
 
Protoplasmic 
Gemistocytic 
Fibrillary 
M : F, 1:1 
0.2/100,000 
  3 (anaplastic)  M : F, 1.4:1 
0.5/100,000 
  4 
(glioblastoma 
multiforme)
 
 
Giant cell 
Gliosarcoma 
M : F, 1.6:1 
2.6/100,000 
1-2.5% GBM 
1.8-2.5% GBM 
 Rarer types 
Subependymal giant 
cell astrocytoma 
Pleomorphic 
xanthoastrocytoma 
Desmoplastic cerebral 
astrocytoma of infancy
 
1 
 
1 
 
1 
  
M > F 
0.51% gliomas, 
M = F 
Rare 
1st 18/12 life 
Rare 
Oligodendrocyte Oligodendroglioma 2  M : F, 1.3:1 
0.3/100,000 
 Anaplastic 
oligodendroglioma 
3  M : F, 1.5:1 
0.1/100,000 
Mixed Oligoastrocytoma 2  M : F, 1.9:1 
0.1/100,000  Anaplastic 
oligoastrocytoma 
3  
 Other mixed   
Ependymal cell Ependymoma 2 Cellular, 
papillary, clear 
cell, tancytic 
M : F, 1.3:1 
0.2/100,000 
 Anaplastic 
ependymoma 
3  
 Myxopapillary 
ependymoma 
1  M : F, 1.6:1 
0.0/100,000 
    
 Subependymoma 1  
Table 1. Classification of gliomas, grade and incidence 
2. Preoperative management 
In the United Kingdom, most patients present through Accident and Emergency. There are 
three main ways they present: with a focal neurological deficit; seizures; or with high 
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intracranial pressure (this is often progressive, but may be sudden onset if the tumour 
bleeds into itself). These presenting symptoms and signs lead to CT/MR as an emergency, 
followed by referral to a neurosurgery unit. If brain oedema is evident on imaging, steroids 
are started.  
2.1 Medications  
Dexamethasone is preferred due to its low mineralocorticoid activity (hence little sodium 
and water retention). The mechanism of action of steroids remains unclear. Dexamethasone 
was introduced in 1960s following Gailicich’s seminal paper on its use of alleviating oedema 
in brain tumours, and it revolutionised the outcome of surgery for brain tumours (Gailicich 
et al, 1961a, 1961b). The standard dose is 4mg four times a day given orally or intravenously, 
following a loading dose of 10mg, and an improvement in symptoms is often seen within a 
few hours (Kesari et al, 2002). If a patient has had a seizure due to their tumour, an 
antiepileptic should be given. Phenytoin is the preferred agent in the acute setting, although 
Carbamazepine may be better for focal seizures. Phenytoin elimination is via zero-order 
kinetics near the therapeutic level and approximately 90% is protein bound. A loading dose 
is required (18mg/kg intravenously), which must be given slowly to reduce risk of 
hypotension and arrhythmias (Meek et al, 1999). The daily dosage is usually 300mg once a 
day, and serum levels should be measured daily until a satisfactory level is achieved. The 
advantages of phenytoin are the fast acting nature and cheap cost. Disadvantages include 
potentially reduced cognitive function, hypersensitivity, megaloblastic anaemia and 
cerebellar degeneration. Phenytoin is teratogenic. Toxicity (which may develop at 
concentrations above 20µm/ml, but more commonly above 30µm/ml) manifests with 
cerebellar signs, confusion and CNS depression. Carbamazepine has a half-life of 20-55 
hours. A low dose should be commenced and incremented slowly, with regular checks of 
haematological function due to its potential for marrow suppressive effects. Its main 
advantages are the low risk of cognitive and dysmorphic side effects. The main 
disadvantages are the unavailability of parenteral form and its metabolic autoinduction 
(Tudur Smith et al, 2002). We will not describe the various antiepileptics here and their 
advantages and disadvantages in detail.  
2.2 Multidisciplinary team 
In most centres, tumours are discussed in a neuro-oncology multi-disciplinary meeting 
(MDT) to determine the best way to proceed with treatment. If patients present as an 
emergency however, their surgical treatment should not be delayed by the MDT. If not an 
immediate emergency, patients with a new diagnosis of glioma can be managed in either 
the inpatient or outpatient setting. A more aggressive approach would be to admit the 
patient directly to the neurosurgical unit from the emergency department or the referring 
hospital, and to plan for surgery on that admission over the following days. A less 
aggressive approach would be to see the patient in the outpatient clinic, especially when a 
“watch and wait” policy is a reasonable option. It is important to note the patient should not 
wait too long to be seen in this setting. Often, little or no information is given to the patient 
from the referring doctors, causing significant anxiety.  
2.3 Conventional imaging  
The practice of imaging of brain tumours has evolved over the past 20 years from a strictly 
morphology-based discipline to one that encompasses function, physiology as well as 
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anatomy. Imaging not only allows determination of the location and extent of tumour but 
also has a key role in primary diagnosis, biopsy target selection, guiding resection margins, 
radiotherapy planning and delineating of tumour from functionally important neural tissue. 
Following treatment, imaging is used to quantify treatment response and extent of residual 
tumour. At follow-up or in the pre-op monitoring of inoperable low-grade glioma, imaging 
helps to determine tumour progression and to differentiate recurrent tumour growth from 
treatment-induced tissue changes, such as radiation necrosis.  
In the majority of cases, plain computed tomography (CT) scans are the first brain imaging 
studies performed when investigating patients with suspected brain tumour. This is because 
CT is widely available, fast, relatively risk-free, and well tolerated. It has the advantage of 
being sensitive in detecting acute haemorrhage, hydrocephalus and mass effect. If an 
abnormality is detected on plain CT then intravenous contrast is administered which allows 
assessment of blood brain barrier (BBB) integrity and delineation of contrast enhancing 
tumour border, if present. Due to its intrinsically low soft tissue contrast, CT is not optimally 
suited for detecting subtle changes in brain parenchyma or patterns of tumour infiltration 
(Ricci, 1999), even with the addition of intravenous contrast agent. CT is inferior to MRI in 
its soft tissue resolution, multi-planar capability and physiology-based applications. Finally, 
CT involves ionizing radiation and its iodinated contrast agent can cause allergic reaction 
(Cha, 2009). 
Magnetic resonance imaging has become the standard of imaging patients with brain 
tumours (Jenkinson, 2007). MR techniques can be broadly classified into ‘conventional’ and 
‘advanced’. Conventional MRI provides qualitative images of normal anatomy and 
pathology, whilst advanced MR techniques allow quantitative and semi-quantitative 
measurement of cerebral blood flow, water movement and the chemical composition of the 
tissue under interrogation. It is these non-invasive methods of assessing tumour physiology 
that are becoming increasingly important in neuro-oncology decision making. In this section 
we will firstly introduce the characteristic glial tumour appearances on conventional MRI 
studies then discuss advanced imaging modalities, focusing on diffusion MR and its 
potential role in tumour diagnosis, delineation and treatment planning.  
2.3.1 Pilocytic astrocytomas (PA), grade I 
PA are slow growing, well circumscribed tumours. Their characteristic imaging appearance 
is of a cystic cerebellar mass with an enhancing mural nodule. They are located in the 
cerebellum in 60% of cases and optic nerve/chiasm in 30% (also adjacent to the third 
ventricle and brainstem). On plain CT, PA form discrete cystic or solid masses with little or 
no surrounding oedema. They contain calcium in 20% of cases, rarely haemorrhage and 
frequently present with obstructive hydrocephalus. Over 95% of PA enhance, but 
enhancement does not indicate malignancy. On T2 weighted and FLAIR MRI scans the solid 
portion is hyperintense to gray matter. Cystic portions are hyperintense to CSF. On T1 
studies, the solid portion is iso/hyponetense to grey matter and there is intense 
hetereogeneous enhancement of the solid portion. The cyst wall occasionally enhances. 
2.3.2 Diffuse astrocytoma (DA), grade II 
Diffuse astrocytomas are typically focal or diffuse non-enhancing white matter lesions. Two 
thirds of DA are located in the cerebral hemispheres (of which 1/3 in the frontal lobe, 1/3 
temporal lobe) and one third are located infratentorially (50% of brainstem gliomas are low 
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grade astrocytomas). DA are tumours of the white matter with only 20% involving deep 
grey matter structures (thalamus or basal ganglia). They may be variable in size and are 
typically homogeneous lesions causing local cortical expansion and distortion of 
surrounding structures. Although they may appear to have a circumscribed edge on 
imaging studies, studies have revealed viable tumour cells are found beyond the image 
margin. Plain CT studies of DA reveal ill-defined hypo or iso dense lesions. Calcification is 
seen in 20% of cases and rarely intra-tumoural cysts. They do not typically enhance 
following the administration of contrast and the presence of enhancement is likely to 
indicate focal anaplastic transformation. Conventional MRI studies of DA (figure 1) identify 
homogeneous, lesions which expand white matter and adjacent cortex. They are typically 
hypointense on T1 weighted MR and hyperintense on T2 weighted and fluid attenuated 
inversion recovery (FLAIR) studies.  
2.3.3 Oligodendroglioma (ODG), grade II 
ODG is a well-differentiated, diffusely infiltrating tumour which typically involves 
subcortical white matter and cortex. 85% of ODG are supratentorially located and are most 
commonly seen in the frontal lobe however may also be present in temporal, parietal and 
occipital lobes, posterior fossa and within the ventricle (1-10%). They may be variable size 
and are most commonly of mixed density of plain CT with calcification seen in 70-90% of 
cases and cystic degeneration in 20%. Approximately 50% enhance following contrast 
administration on both CT and MRI. On T1-weighted MRI studies ODG are heterogeneous 
and hypo or isointense to grey matter. They are cortical and subcortically located and cause 
surrounding cortical expansion. They are hyperintense on T2/FLAIR. Anaplastic 
oligodendroglioma (AO), have similar appearances as ODG however will contain foci of 
malignant progression which may be seen as new contrast enhancement, necrosis, cystic 
change or haemorrhage. 
2.3.4 Anaplastic astrocytoma (AA), grade III 
In common with DA, anaplastic astrocytomas are infiltrating lesions predominantly 
involving white matter. AA are more commonly within the cerebral hemispheres (especially 
temporal lobes), they may be of variable size and may appear well-circumscribed however, 
as in DA, tumour cells are almost always found beyond the tumour border on imaging. On 
CT studies, AA are low density, ill-defined mass. They rarely contain calcification and the 
majority do not enhance (those that do display patchy foci of enhancement). On T1 
weighted MR imaging they are mixed isointense to hypointense white matter lesions. They 
are heterogeneously hyperintense on T2 weighted and FLAIR MR. Evidence of ring 
enhancement, prominent flow voids and cysts may suggest progression of AA to more 
malignant forms. 
2.3.5 Glioblastoma multiforme (GBM), grade IV 
GBM are most commonly located in supratentorial white matter within the frontal, temporal 
and parietal lobes however may infiltrate across white matter pathways to involve 
contralateral cerebral hemisphere. They may be of variable size and morphology. Most 
frequently they are poorly marginated, diffusely infiltrating necrotic lesions, which in rare 
cases are multifocal or multicentric. GBM appear as irregular, isodense or hypodense lesions 
with central necrotic hypodensity on plain CT. They frequently exert significant local mass 
effect and have peri-tumoural oedema and tumour infiltration. Of all glial tumours, GBM 
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are the most likely to contain haemorrhage. Conventional MRI of GBM (figure 2), reveal 
irregular iso or hypo intense masses on T1 weighted studies and heterogeneous 
hyperintense masses with adjacent oedema/tumour infiltration on T2 weighted/FLAIR 
MRI. GBM frequently contain a necrotic core, tumoural cysts, focal haemorrhage, and flow 
voids secondary to tumour neovascularity. GBM most commonly have thick irregular 
enhancing margins surrounding central necrosis however may exhibit solid, ring or patchy 
enhancement on gadolinium enhanced T1 weighted MRI. 
 
A B
C D
 
Fig. 1. MRI images of left fronto-temporal diffuse astrocytoma. A. T2-weighted image, B. 
Fluid attenuated inversion recovery (FLAIR) image, C. T1-weighted image following 
administration of 0.1 mmol/kg gadoterate meglumine, Dotarem), D. T1-weighted image. 
2.3.6 Ependymoma grade II or III 
Ependymoma are slow growing tumours of ependymal cells, of which, 2 / 3 are 
infratentorially located (typically within the IVth ventricle) and 1 / 3 supratentorial (within 
periventricular white matter). They are of irregular shape, typically modelling to the shape 
of the ventricle or cistern. 50% of ependymomas calcify and they are heterogeneous lesions 
(iso or hypo inetense on T1 and T2 MRI) and display irregular degrees of enhancement.  
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2.3.7 Rare gliomas 
Gliosarcoma (grade IV). Gliosarcomas are rare malignant neoplasms containing both glial 
and mesenchymal elements. Although their imaging appearances are often 
indistinguishable from GBM, they more commonly exhibit dural invasion and involvement 
of surrounding skull. In common with GBM, they infiltrate white matter and are typically 
supratentorially located however may have a discrete portion. They are heterogeneous 
masses with thick irregular enhancement on CT and share the features of GBM on 
conventional MRI, as a result gliosarcoma are frequently only identified following formal 
tumour histological analysis. 
 
A B
C D
 
Fig. 2. MRI images of left temporal glioblastoma. A. T2-weighted image, B. Fluid attenuated 
inversion recovery (FLAIR) image, C. T1-weighted image, D. T1-weighted image following 
administration of 0.1 mmol/kg gadoterate meglumine, Dotarem) 
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Gliomatosis cerebri (grade IV). Gliomatosis cerebri (GC), are diffusely infiltrating 
glioblastoma lesions involving two or more lobes of the brain and a frequently bilateral. 
Although they are typically hemispheric they may involve cortex in 19% of cases and as well 
as diffuse white matter may involve basal ganglia/thalami (75%), corpus callosum (50%), 
brainstem/spinal cord (10-15%) and cerebellum (10%). GC are infiltrative in nature, yet may 
preserve underlying brain architecture and cross the midline via corpus callosum or massa 
intermedia. GC may exhibit subtle asymmetric loss of grey-white differentiation and mild 
mass effect on plain CT and do not typically enhance (focal enhancement may indicate 
malignant progression or a focus of anaplastic change). They are iso or hypo intense on T1 
weighted MR and homogenously hyperintense on T2-weighted/FLAIR MRI. 
Pleomorphic xanthoastrocytoma (PXA), grade II. PXA are a distinct type of benign, 
supratentorial (98% of cases), astrocytoma affecting young adults. Their characteristic 
feature is of a cortical mass with adjacent enhancing dural ‘tail’ with an associated tumour 
cyst (50-60% of cases) and mural nodule. They are most commonly seen in the temporal lobe 
and may be of variable size. Despite their circumscribed appearance they often infiltrate into 
brain. On CT, PXAs are hypodense with a mixed density nodule, they have minimal 
surrounding oedema and typically avidly enhance. On T1 weighted MRI, they are hypo or 
isointense to surrounding grey matter and enhance following administration of gadolinium. 
The solid portion is hyperintense or of mixed signal intensity on T2-weight or FLAIR 
studies. Any cystic portions are isointense to CSF. 
2.4 Advanced imaging 
Despite its superb soft tissue contrast, multi-planar capability and non-invasive nature, 
conventional MRI is largely limited to depicting morphological abnormalities. Different 
disease processes can appear similar on anatomic imaging, and conversely a disease entity 
may have varied imaging findings. The underlying metabolic or functional integrity of brain 
cannot be adequately evaluated on anatomical MRI alone. To that end, several physiology-
based MRI methods have been developed to improve tumour characterisation including 
spectroscopy, radionuclide imaging (PET and SPECT), dynamic susceptibility contrast MRI, 
blood oxygen level dependent (BOLD) MRI and diffusion imaging. 
2.4.1 Magnetic resonance spectroscopy (MRS) 
Proton MRS can be used to non-invasively evaluate the biochemical structure of tumour 
tissue and has been used as an adjunct to conventional MRI to diagnose ‘likely’ tumour 
grade prior to surgery, guide stereotactic biopsy, plan radiotherapy margins and 
differentiate radiation necrosis from tumour recurrence. Spectroscopy signals are either 
localised from a single selected voxel or from multiple voxels (also known as chemical shift 
imaging). Proton spectra reveal varying peaks at defined resonant frequencies. The 
commonest peaks studied in brain tumours are: 
i. N-acetyl aspartate (NAA): reduced in disorders resulting in axonal loss therefore 
considered a surrogate marker of integrity of the neurone.  
ii. Choline (cho): choline compounds involved in breakdown and manufacture of cellular 
membranes. Choline increases with membrane turnover. 
iii.  Creatine (Cr): involved in energy metabolism (ATP synthesis) 
iv.  Lipid: not normally seen in brain. Their presence indicates membrane breakdown and 
necrosis. 
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v.  Lactate: levels increase in situations of anaerobic glycolysis 
Glial tumours have a reduced NAA/Cr ratio and spectroscopic profiles such as high lactate 
and lipids are indicative of malignant tumour. Tumour cell density may be reflected by the 
magnitude of choline peak and choline:NAA ratio. MRS is useful in distinguishing 
neoplastic from non-neoplastic lesions however owing to the lack of reproducible 
‘metabolite profiles’ of glial tumour subtypes, its role in routine diagnosis has yet to be 
elucidated. 
 
Astrocytoma III
Astrocytoma II
Glioblastoma
Lac
tCr
tCho
mI
Lipid
Lac/Lipid
Lipid
MM
tCr
tCho
5 4 3 2 1 0  
Fig. 3. Characteristic spectroscopic profiles of glial tumours. Choline (tCho) is considered a 
marker of tumour cell membrane proliferation and is seen to increase with tumour grade. 
Similarly an inverse relationship between NAA/Cr and Cho/Cr ratio and tumour grade 
may be used to differentiate high grade from low grade glioma. Higher lipid levels are seen 
in GBM, presumably a result of necrosis. Higher lactate levels with higher grades.  
2.4.2 Diffusion imaging 
The development of MR pulse sequences sensitised to the movement of water molecules has 
enabled visualisation and mathematical characterisation of the magnitude and direction of 
water diffusion within the brain. Diffusion weighted imaging was introduced into routine 
practice in the 1990s, and generation of maps of apparent diffusion coefficient (ADC) have 
been used to differentiate cystic lesions (arachnoid from epidermoid cysts) and abscess from 
tumour. Numerous studies have been performed to characterise the glial tumour 
environment using ADC values which are affected by both the extent of local vasogenic 
oedema and the degree of tumour cellularity. Despite several studies confirming a 
correlation between celularity and ADC, a tumour-specific DWI profile has not been 
identified. The underlying assumption of DWI is that water diffusion occurs in all directions 
(i.e. is isotropic). Investigators proposed that diffusion is likely to be restricted and 
directional (anisotropic) due to the influence of local intra and extra cellular structures such 
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as white matter fibres and myelin sheaths. Mathematical determination of the resultant 
diffusion ellipsoid requires the use of a tensor, which contains information about the 
magnitude and principal directionality of diffusion on a voxel scale. This information has 
enabled calculation of rotationally invariant indices such as mean diffusivity (MD) and 
fractional anisotropy (FA) as measures of isotropic and anisotropic diffusion respectively. 
These metrics have been applied to a range of intracranial pathology and studies have 
revealed relationships between FA and tumour cell density and have attempted to 
characterise the peri-tumoural oedema of low and high-grade glioma yet this has yet to be 
used routinely in clinical practice. The most promising role for diffusion tensor imaging in 
glial surgery is its application in tractography. Use of this technique has allowed:  
i. Definition of the anatomical relationship of a tumour to local white matter pathways, 
which may be incorporated on to image guidance systems to guide the surgical 
approach intra-operatively. 
ii. Evaluation of whether there is displacement, invasion or destruction of surrounding 
white matter tracts by tumour. 
iii. Knowledge of location of white matter tracts may assist intraoperative fibre stimulation 
and guide extent of resection 
iv. Evidence of intact pathways following surgery may predict motor deficits and recovery. 
Although the strong similarity between generated white matter structures using DTI 
tractography and post mortem anatomical dissection, the technique is unable to accurately 
define the anatomy of individual axons and may be complicated by crossing fibres thus, at 
present, it role is primarily for macroscopic delineation of tract configuration. 
 
 
Fig. 4. A 6-year-old child with tumor arising from the brainstem. a Axial FLAIR image 
shows a tumor within the right middle cerebellar peduncle (arrow). b Axial color map shows 
loss of anisotropy within the right medial lemniscus resulting in lack of blue (short arrow). 
The right corticospinal tract (long arrow) is attenuated and has diminished anisotropy. C 
Coronal image derived from tractography shows leftward displacement of the right 
corticospinal tract (Rollins, 2007). 
3. Common brain gliomas – surgical management  
3.1 Glioblastoma multiforme (grade IV)/ anaplastic astrocytoma (grade III) 
Grade III and grade IV astrocytomas are also called high-grade tumours. If the patient is 
young and the tumour “resectable,” the primary aim is to remove as much as possible. The 
greater the extent of tumour removed, the better the time to tumour progression and 
www.intechopen.com
 Neurosurgical Management of Gliomas 
 
413 
survival (Keles et al, 1999). Surgery not only prolongs life, but also improves quality of life 
and the effectiveness of adjuvant therapy (Abrudan et al, 2011, Kiwit et al, 1996; Ryken et al, 
2008). When considering surgery, three of the most important prognostic factors for 
surgeons are the patient age, the tumour grade and the patient’s performance status 
(Karnofsky score) at presentation (Buckner, 2003; Wu et al, 2010). Each is an independent 
factor for survival; favouring survival is younger patient age, Karnovsky score  70 
(meaning independence) and lower tumour grade. Tumour resectability predominantly 
refers to the tumour location and the ability to remove the tumour without leaving the 
patient dead or moribund. Superficial, non-eloquent lesions (e.g. non dominant frontal) are 
considered highly resectable. Non-resectable lesions include deep, eloquent brain e.g. 
brainstem gliomas. Another subset that fall under the non-resectable lesions are butterfly 
gliomas, so called due to their characteristic radiological appearances based around the 
corpus callosum, extending bifrontally. These often occur in elderly patients and treatment 
is usually biopsy alone. Prognosis is dismal (Agrawal, 2009).  
Surgery is simple in most cases, the aim is to remove as much tumour as possible without 
causing damage to brain. A craniotomy is performed at the required location, followed by 
debulking of the tumour with suction and/ or Cavitron Ultrasonic Surgical Aspirator 
(CUSA). Suction pulls on surrounding brain tissue, CUSA advantageously does not. High-
grade tumours are highly vascular, and may bleed substantially during surgery. It is 
common to encounter necrosis and thrombosed vessels intraoperatively. This is surgical 
evidence of a high-grade lesion. With substantial bleeding, it is important to continue 
resecting, as once the tumour and associated abnormal blood vessels are removed, the 
bleeding will stop. Do not fall into the trap of stopping every few seconds to assess and 
coagulate as this will take too long, will increase blood loss and will probably result in less 
tumour removed. The tumour often feels tougher than brain, and any cystic components 
have a characteristic straw coloured fluid. Surgical judgement (from feel and experience) is 
required to know when to stop resecting. These are diffuse tumours and therefore there is 
no clear margin. There is a continuum from what is all tumour to more and more percentage 
of brain mixed with tumour, and when to stop depends also on the eloquence of adjacent 
brain. At the end of the operation, haemostasis is imperative. This is achieved with a 
combination of coagulation, Surgicel, and woolly balls. Surgicel and woolly balls will only 
stop venous bleeding. We always ask the anaesthetist to increase the patient’s blood 
pressure to normal before closing. Any arteries in spasm will then begin to bleed. It is 
obviously important to know this before closing, so that we coagulate rather than ignore any 
unaddressed bleeding to avoid postoperative haematoma!  Once we are satisfied the 
operative field is dry, we close up and the operation is finished (Schmidek, 2005; Slacman M, 
1996).  
Some centres operate on high-grade tumours awake. The patient is anaesthetised for the 
skin incision and craniotomy parts. The patient is woken once the brain and tumour is 
exposed. This allows the surgeon to maximise tumour resection without causing a disabling 
neurological deficit. Awake surgery is not widely accepted for GBM and anaplastic 
astrocytoma due to their aggressive and infiltrative nature. Although there is well-
documented evidence of a significant difference in outlook between a small biopsy vs. 
extensive resection (Arudan et al, 2011; Keles et al, 1999; Ryken et al, 2008) there is probably 
little to be gained  in outlook between extensive resection versus achieving another small 
percentage resection with awake surgery.  
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Recently, some surgeons advocated the intraoperative use of fluorescent dye, 5-
aminolevulinic acid (5-ALA), although currently this is not widely used. 5-ALA is a natural 
biochemical precursor of haemoglobin, which results in accumulation of porphyrins within 
malignant glioma tissue. Its selective intratumoural synthesis enables an accurate 
delineation of the tumour boundary, seen via a modified neuromicroscope. 5-ALA has been 
shown to improve gross total resection defined by early post operative MRI, as well as 
improve 6 month progression free survival (Stummer et al, 2006).    
Neuronavigation (e.g. Stealth, see figure 5) is another aid to glioma surgery. This utilises 
preoperative CT and/or MRI images to map the patient’s anatomy in a 3-dimensional 
configuration, calibrated using specific landmarks on the patient. It can be used to map the 
bone flap and to guide debulking of the abnormal tissue. The main disadvantage of this 
widely used technique is that the brain moves once the skull and meninges are opened, thus 
diminishing the accuracy of the neuronavigation (Warnick & Bath, 2002). Newer techniques 
include the use of intraoperative ultrasound. This allows for an updated picture on each 
application of the ultrasound wand, and therefore corrects for any intraoperative brain shift 
with almost realtime information on the tumour location and extent. The financial cost of 
this is high. 
If a tumour is deemed unresectable but there has been an agreement to give adjuvant 
treatment, a biopsy is required for histological confirmation of grade. This can be performed 
either Stealth or stereotactic guided. The former is frameless, the latter is a frame guided 
system. Both yield a similar diagnostic accuracy with similar complication rates (Doward et al, 
2002). Grade III glioma treatment is the same as for grade IV, including maximal resection if 
possible followed by radiotherapy and temozolomide. PCV chemotherapy (procarbazine, 
lomustine and vincristine) is used as a second line (Theeler & Groves, 2011). 
3.1.1 Other considerations in high grade gliomas 
Gliadel wafers. These are made by MGI pharma, Inc and contain polifeprosan 20 with 
carmustine implant, an alkylating agent used for brain and bone marrow tumours. Their use 
at the time of surgery improves survival in good performance status patients (Karnovsky  
70) by 2.5 months compared to placebo. There is no survival benefit in recurrent high-grade 
glioma. The main side effects are cerebral infections, CSF leak, cerebral oedema and healing 
abnormalities, and this is why not everyone uses them (Hart et al, 2011).  
Temozolamide. Temozolomide is used routinely as adjuvant chemotherapy for high grades. 
It improves survival and time to progression, without any increase in adverse events. 
Tumour tissue is analysed for O-6-methylguanine-DNA methyltransferase (MGMT) 
expression, as this enzyme diminishes the therapeutic efficacy and thus these patients 
receive little benefit from temozolamide (Theeler, 2011).  
New treatments. Bevacizumab is a humanised monoclonal antibody against vascular 
endothelial growth factor (VEGF), necessary for tumour angiogenesis. Although there is no 
level 1 evidence yet, there have been impressive results of progression free survival in some 
cases in patients with recurrent high grade glioma (Iwamoto & Fine, 2010; Friedman et al, 
2009). With the advent of new treatments beginning to improve outcome, this raises 
questions about reoperation for high grade gliomas. This is a controversial topic, with views 
across the spectrum. The advantages of reoperation are (i) it has been shown to extend 
survival compared with medical treatment alone and (ii) it allows for direct local delivery of 
chemotherapeutic agents. The disadvantages of reoperation are more time spent in hospital, 
and increased risk of complications, which may outweigh a potential survival benefit. 
(Brandes et al, 1999; Niyazi et al, 2011). Given that oncologists have more treatments to give 
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after reoperation, perhaps we should be considering a larger role for surgery and 
redebulking in recurrent high-grade glioma. 
 
 
 
Fig. 5. Neuronavigation Stealth. 
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Glioblastoma subtypes. Gliosarcoma may metastasise extracranially. There are distinct 
gross macroscopic features described: a firm, well circumscribed lesion; and an infiltrative 
poorly defined lesion. Treatment and prognosis is similar as for GBM (Han et al, 2010). 
Giant cell GBM, another rare subtype, is treated in a similar fashion. Data suggests 
prognosis may be better in this subgroup compared to GBMs as a whole, especially 
considering long term survival (Kozak & Moody, 2009).  
3.2 Grade II astrocytomas and oligoastrocytomas 
There is no gold standard of treatment and management is controversial ranging from a 
wait and see policy with serial imaging, to biopsy, to maximal debulking. The role and 
timing of adjuvant radiotherapy and chemotherapy is also unclear, and is currently being 
investigated. There are 5 prognostic features which indicate a high risk low grade gliomas: 
astrocytoma histology, age over 40 years, tumours over 6cm, tumour crossing the midline, 
and presence of a neurological deficit. Some surgeons advocate resection followed by 
radiotherapy for these high risk patients (Pignatti et al, 2002; Ruiz & Lesser, 2009). 
Awake surgery is well-established for low grade gliomas. The patient undergoes a general 
anaesthetic for the craniotomy, and is woken when the tumour is exposed. The anaesthetist 
runs through relevant tests of speech or motor function whilst the gyri adjacent to the tumour 
are stimulated to map the sensorimotor cortex. It is evident if eloquent brain is involved, as the 
patient may transiently become dysphasic, develop a motor weakness or experience a 
sensation down a limb. The surgeon is therefore able to map and avoid resection of this 
eloquent brain.  The patient must be able to understand the procedure and tolerate surgery 
awake; the patient must be able to cooperate; the tumour should be close to eloquent motor or 
speech areas which can be tested adequately intraoperatively by stimulation and testing 
function; the patient must be a suitable candidate for and has consented to adjuvant treatment, 
as awake surgery in itself would otherwise be ineffective; at least 90% tumour resection is 
anticipated. There have only been two small prospective randomised controlled studies 
directly comparing awake versus asleep craniotomy for intrinsic brain lesions. There appears 
to be no difference in outcome at 3 and 6 months (Ali et al, 2009; Gupta et al, 2007). However 
the long term results, which are more important, are not known. 
Intraoperatively low-grade tumours can look and feel almost like normal brain. A slight 
discolouration may indicate tumour or brain swelling and it is often difficult to differentiate 
between the two. Again, surgical experience is required to judge when to stop. 
Intraoperative MRI is a tool aimed at maximising tumour resection. Although intraoperatine 
MRI has been shown to improve the percentage of tumour resected, its use can be very time-
consuming and there is currently no data available to show improved survival benefit (Senft 
et al, 2010).  
The different histological subtypes of grade II gliomas are described in table 1. The variants 
are not prognostically important, except the gemistocytic subtype (Greek word meaning 
stuffed cells). These tumours behave more aggressively than their grade suggests and most 
oncologists will therefore treat these patients with radiotherapy and chemotherapy upfront 
(Krouwer et al, 1991).  
3.3 Grade I pilocytic astrocytoma   
These often benign lesions comprise of a cyst and solid component. The solid component 
often enhances, and, is the exception to the rule, in that enhancement enhancement does not 
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mean malignancy. They are found mostly in children and occasionally in young adults, and 
are located most commonly in the posterior fossa. Pilocytic astrocytoma is not a diffuse 
tumour. Supratentorial pilocytic astrocytomas tend to be more aggressive. Pilocytic is a 
Greek word meaning “hairlike,” so called due the appearance of the cells under a 
microscope. An important surgical point to note is that the cyst wall is not part of the 
tumour. Attempted maximal resectionof the solid component is often curative without the 
need for other treatment. If there is complete removal in infratentorial lesions, there is no 
need for long term follow up however the presence of worrying features eg supratentorial, 
or evidence of growth, serial MR are recommended (Fernandez et al, 2003; Krieger et al, 
1997).  
3.4 Rare grade I gliomas: Pleomorphic xanthoastrocytoma, desmoplastic cerebral 
astrocytoma of infancy and subependymal giant cell astrocytoma (SEGA)  
Pleomorphic xanthoastrocytomas are most often benign tumours that tend to present in 
patients under the age of 30, with seizures in the majority of cases. Intraoperatively they are 
often well defined and in close meningeal contact (Van Rooset et al, 1996). Desmoplastic 
astrocytoma of infancy is a rare subtype that presents as a large hemispheric mass in infants. 
Radiological features are typically of a large enhancing mass with a peripheral dural based 
component and a central cystic component. Despite worrisome features, these tumours 
respond to gross total resection and prognosis is generally favourable (Serra et al, 1996; Uro-
Coste et al, 2010). Subependymal giant cell astrocytomas (SEGA), part of the Tuberous 
Sclerosis complex, are slow growing, benign intraventricular lesions. Historically, surgical 
resection has been advocated however medical treatment with the mTor inhibitor 
Everolimus has been shown to reduce tumour size with good seizure control, and may 
become the hallmark of treatment for these tumours (Krueger et al, 2010; Sharma et al, 2004).    
3.5 Oligodendroglioma  
These WHO grade II lesions tend to be more benign, and have characteristic appearances of 
intralesional calcification on CT. Extensive resection followed by a watch and wait policy is 
an accepted treatment. 1p19q codeletion is a predictor of chemosensitivity and of improved 
prognosis in these tumours (Thiessen et al, 2003). Anaplastic variants should have adjuvant 
chemo/radiotherapy (Quon & Abdulkarim, 2008). 
3.6 Ependymoma 
These tumours are located predominantly in the posterior fossa and commonly present with 
obstructive hydrocephalus. Treatment is surgical resection followed by radiotherapy (Reni 
et al, 2007; Stuben et al, 1997). Subependymomas are slow-growing, benign lesions typically 
found in the ventricular system and may remain asymptomatic throughout life. They are 
well defined radiologically with little or no enhancement. Given their indolent nature, 
surgery should err on the side of caution i.e. on leaving tumour behind rather than causing a 
neurological deficit (Ragel et al, 2006). 
4. Spinal cord gliomas  
Primary malignant spinal cord gliomas are rare, occurring in 0.12 per 100,000 population, 
with an increase in ependymomas over the past three decades (Hsu et al, 2011). They 
usually present with progressive symptoms of numbness and tingling and loss of power. 
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Pain tends to be a prominent presenting feature, its nature of which is constant and poorly 
localised waking the patient at night, and it often precedes any neurological symptoms. 
Back pain that wakes the patient up at night without local tenderness is most often caused 
by an intrinsic tumour, ependymoma or astrocytoma. The signs are of a progressive 
myelopathy and may lead to a rapid quadri/paraparesis  
The most common tumour type is ependymoma, followed by astrocytoma. There are 
characteristic MRI radiological appearances, which include an intrinsic expansive cord 
lesion with variable contrast enhancement, and often cystic components. Surgery is the first 
line treatment in ependymomas, with enbloc resection and primary dural closure if possible. 
CUSA is employed for resection, as well as the microscope. Gross total resection is 
associated with a high complication rate but good outcome and low recurrence rates. Extent 
of resection depends on how stuck the tumour is. Complete resection is only possible if 
located at the conus and not stuck, or at filum terminale. If stuck at the conus, tumour 
should be left behind to avoid disabling complications. Although not radiosensitive or 
chemosensitive, patients can go on for many years without any deterioration. Overall 
progression free survival is 89% and 84% at 5 and 10 years respectively (Kucia et al, 2010). 
Tumours are technically more difficult if higher than conus medullaris, although it still may 
be possible to remove completely. Intraoperative use of somatosensory evoked potentials 
and motor evoked potentials can help predict and even prevent post operative neurological 
deficit, although they may add to length of operation (Kearse et al, 1993; Kelleher et al, 
2008). Low-grade astrocytomas are less curable with approximately 50% gross total 
resection and favourable survival outcome. Little is known about them as they are rare 
(Benes et al, 2009; Nakamura et al, 2008). High-grade spinal cord tumours (grade III 
astrocytomas and glioblastoma multiforme) carry a far worse prognosis. Given the rare 
nature of these tumours, actual outcome is again not known, and no centre has extensive 
experience. Retrospective studies have shown gross total resection is rarely possible, and 
most patients die of disease progression. Mean survival is quoted at 6 – 19 months for grade 
III and IV spinal cord gliomas. Therefore these tumours are probably just as lethal as their 
brain counterparts (Cohen et al, 1989; McGirt et al, 2008; Raco et al, 2010). Treatment is the 
same with debulking, radiotherapy and temozolomide, but often an extensive debulking as 
with brain GBM is not possible, and the maximum amount of targeted radiotherapy is also 
less than with brain GBM. For these two reasons – less debulking, less radiotherapy – the 
outcome of spinal cord GBM is probably worse than the outcome of brain GBM. One 
intriguing possibility that has yet to be explored is to remove the tumour en block with a 
margin of cord above and below. Obviously this would only be possible in thoracic region, 
and in a patient with no neurological function below the level of tumour. The theoretical 
advantage would be improved survival benefit. A theoretical disadvantage would be to 
convert a spastic paraplegia to a flaccid one.  
5. Paediatric gliomas  
Malignant non brain stem gliomas represent 8-10% of paediatric CNS tumours (Hargrave 
2009). It is likely the molecular biology of childhood GBM is similar to that of adult GBM, 
however this is not as well described in the paediatric population. They are usually located 
supratentorially, but unlike adults, high grade gliomas are significantly less common than low 
grades (Pollack, 1994). As is adults, these are treated with maximal surgical resection followed 
by chemo/radiotherapy (Sposto et al, 1989). Diffuse intrinsic brain stem gliomas constitute 15-
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20% of all CNS tumours in children, and are their main cause of death (Hargrave et al. 2006). 
These have characteristic radiological appearances that expand the brainstem with an 
epicentre situated in the pons. They do not benefit from biopsy and radical surgery is 
impossible. In exophytic and focal brain stem gliomas, however, surgery is the treatment of 
choice with radiotherapy reserved for recurrence. The prognosis is better, with 90% alive at 2 
years, compared to 25% alive at 2 years in the diffuse group (Mauffrey, 2006). 
6. Conclusion  
In this Chapter we discussed the commonest types of brain tumour, the gliomas. Surgery is 
an important aspect of the management of these tumours but the extent of surgical 
involvement remains controversial. Unfortunately little progress has been made in this field 
over the last 20 years such that the outlook of patients with gliomas has not substantially 
improved over this period.  
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established and newly-arising techniques to diagnose central nervous system tumors, with a special focus on
neuroimaging, followed by a discussion on the neurosurgical guidelines and techniques to manage and treat
this disease. Each chapter in the Diagnostic Techniques and Surgical Management of Brain Tumors is
authored by international experts with extensive experience in the areas covered.
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